Risk Intervention Study: Cisapride
description
Transcript of Risk Intervention Study: Cisapride
![Page 1: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/1.jpg)
1
Risk Intervention Study: Cisapride
Evelyn M Rodriguez MD, MPHDirector, DDREII, OPDRA
![Page 2: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/2.jpg)
2
Topics for Today’s Discussion
• Cisapride: Risk Intervention Case Study
• Summary / Considerations• Future Directions
![Page 3: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/3.jpg)
3
Cisapride’s Regulatory History
Risk Intervention Study
![Page 4: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/4.jpg)
4
Cisapride’s Regulatory History
• Approved in July 1993 • First reports of Ventricular Arrhythmia
with an antifungal drug 12/94• Multiple Dear Healthcare Practitioner
letters that described new contraindications and warnings for specific drugs and conditions
![Page 5: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/5.jpg)
5
Cisapride’s Regulatory History
• Black Box Warning with Contraindication for QT interval prolonging drugs and Cardiovascular and Medical Conditions, 2nd line indication & DHPL 6/98
![Page 6: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/6.jpg)
6
Study Objective
• To describe the impact of the cumulative labeling changes through 6/98–CYP P450 3A4 Enzyme Inhibitor
Drugs–QT Prolonging Drugs–Contraindicated Comorbidities
![Page 7: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/7.jpg)
7
Methods• Automated Databases:
–Sites A, B, and C• Time Periods
–Before DHPL: 7/97 - 6/98–After DHPL: 7/98 - 6/99
![Page 8: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/8.jpg)
8
Study Sites
Model N, Millions
A IPA 3.2
B Medicaid Managed 1.4
C HMO 2.2N based on calendar 1998; no material change for any of databases in 1999.
![Page 9: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/9.jpg)
9
Cohorts Before and After Labeling Changes through
6/98Pre Post
Site NA 16,934 15,088
B 4,823 4,924
C 8,271 7,508
![Page 10: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/10.jpg)
10
Results: Contraindicated Drug or Disease
Pre Post
Site % of Cohort
A 29.4 26.6
B 59.7 57.5
C 29.6 27.5
![Page 11: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/11.jpg)
11
Conclusion
• No reduction in contraindicated use was found following labeling changes and DHPL of 6/98
![Page 12: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/12.jpg)
12
Study GroupFDA Investigators
Diane Wysowski Ph.D., Evelyn M. Rodriguez, Dave Graham M.D., M.P.H.
United Health Group (Site A)
Deborah Shatin, Ph.D., Stephanie D. Schech, Ph.D.
Tennessee Medicaid (Site B)Walter Smalley, M.D., M.P.H., Jim Daugherty, M.S., Wayne Ray, Ph.D.
Harvard Consortium (Site C)Jerry Gurwitz, M.D, Susan Andrade, D.Sc., Jackie Cernieux, M.P.H. (Meyers Primary Care Institute, Fallon Healthcare System); Richard Platt, M.D., M.S., Arnold Chan, M.D., Dr.P.H. (Harvard Pilgrim Healthcare, Michael Goodman, Ph.D. (HealthPartners)
![Page 13: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/13.jpg)
13
Summary / Considerations• Risk Intervention studies are useful to
assess the effect of labeling and DHPL• This study suggests labeling fatigue• Other strategies, such as Education
targeting Prescribers and Patients, may be useful to encourage the implementation of recommended risk management efforts
![Page 14: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/14.jpg)
14
Future Directions• Determine
–How prescribers interpret information from DHPL & other educational materials
–Best format to inform prescribers and patients of drug safety concerns -- PPI, Med Guide, company sales force materials, CME course
![Page 15: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/15.jpg)
15
Future Directions
• Determine –How information,
contraindications, and monitoring recommendations are used
![Page 16: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/16.jpg)
16
Future Directions
• Conduct risk intervention studies in multiple databases that reflect the range of health care services delivery systems
• Validate the findings in databases with medical record review
![Page 17: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/17.jpg)
17
Possible Next Steps• Incidence Study for Serious
Outcomes–QT Prolongation and Torsades de
Pointe difficult to assess (non-specific ICD-9 codes and underreporting)
–Sudden Death possible; use unexposed comparator group
![Page 18: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/18.jpg)
18
Possible Next Steps
• Implement Risk Interventions: EKG monitoring, other
• Evaluate whether the Risk Interventions (e.g. Education, Labeling) is achieving desired goals
![Page 19: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/19.jpg)
19
Back Up Slides
![Page 20: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/20.jpg)
20
Pre (%) Post (%)Site A: Any 14.4 12.6 P450 3A4 7.4 5.5 QT-Label 4.0 4.1 QT-Class 8.1 7.9
Site B: Any 33.8 33.6 P450 3A4 10.4 9.8 QT-Label 11.4 12.0 QT-Class 26.5 26.4
Site C: Any 18.3 16.1 P450 3A4 9.3 7.5 QT-Label 5.4 5.2 QT-Class 10.4 9.7
Contra-indicatedDrugs
![Page 21: Risk Intervention Study: Cisapride](https://reader036.fdocuments.us/reader036/viewer/2022062316/56816791550346895ddcc49c/html5/thumbnails/21.jpg)
21
Contraindicated ComorbidityPre Post
Site %A 14.9 14.0
B 41.3 38.8
C 15.3 14.5
Based on (pre/post) persons with 180+ days of enrollment: Site A: 13613/12418; B: 4379/4229; C: 6848/5812